Views & Analysis Searching for new hope in Alzheimer’s For the best part of two decades, it seemed as if pharma hit a brick wall as it tried to find new treatments for Alzheimer’s.
R&D Citing phase 2 figures, Axon looks for big pharma investment... After trial failure upon trial failure in Alzheimer's disease will big pharma be prepared to fund a trial using a new approach instead of the amyloid-targeting drugs, that have caused so mu
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
